Skip to main content
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. — Investor Relations & Filings

Ticker · ORKA ISIN · US6876041087 US Manufacturing
Open in API
Filings indexed 997 across all filing types
Latest filing 2025-03-12 Regulatory Filings
Country US United States of America
Listing US ORKA

About Oruka Therapeutics, Inc.

https://orukatx.com/

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel biologics for chronic skin diseases and other inflammatory conditions. The company applies advanced antibody engineering to validated modes of action to create potentially best-in-class monoclonal antibodies. Its lead program, ORKA-001, targets the IL-23 cytokine for the treatment of moderate-to-severe plaque psoriasis. Oruka's mission is to redefine the standard of care by developing treatments that achieve high rates of complete disease clearance with a significantly reduced dosing frequency, potentially requiring only one or two doses per year.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-03-12 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-03-11 English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to Form S-1 Registration Statement filed with the SEC by Oruka Therapeutics, Inc. It references the inclusion of the fiscal year ended December 31, 2024 financial statements contained in the Form 10-K for the year ended December 31, 2024 filed on March 6, 2025. The document is a registration statement amendment related to securities offering and resale by selling stockholders, including detailed prospectus information, risk factors, management discussion and analysis, and other disclosures typical of a registration statement. It is not an annual report itself but an SEC filing related to securities registration and offering. Form S-1 and its amendments are capital markets filings related to registration of securities for public offering. Therefore, the filing type corresponds to Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is substantial in length and content, not a mere announcement or certification, and focuses on securities registration and resale prospectus.
2025-03-06 English
REGISTRATION STATEMENT
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Oruka Therapeutics, Inc. It registers additional shares under the company's 2024 Stock Incentive Plan and 2024 Employee Stock Purchase Plan. The document includes legal exhibits, consents, and signatures but does not contain financial statements or performance data. Form S-8 is specifically used for registering securities to be offered under employee benefit plans and is a capital markets filing related to share issuance. Therefore, this document is best classified under Share Issue/Capital Change (SHA). The document length and content confirm it is the registration statement itself, not just an announcement or certification.
2025-03-06 English
ANNUAL REPORT
Annual Report FY 2024
2025-03-06 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-28 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.